Sonnet biotherapeutics to present clinical data from the sb101 study with son-1010 at the aacr 2023 annual meeting

Princeton, nj / accesswire / march 14, 2023 / sonnet biotherapeutics holdings, inc. (nasdaq:sonn) ("sonnet" or the "company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today that data from the company-sponsored sb101 multiple-dose clinical trial (nct05352750) of son-1010 (il12-fhab) in adult patients with advanced solid tumors will be presented in a poster session at the upcoming american association for cancer research (aacr) annual meeting 2023, to be held april 14-19, in orlando, florida. presentation details: title: clinical development of a novel form of interleukin-12 with extended pharmacokinetics session title: phase i and first-in-human clinical trials in progress presentation type: poster session date and time: tuesday april 18, 2023, 1:30 pm - 5:00 pm abstract number: ct245 location: poster section 46 about sonnet biotherapeutics holdings, inc. sonnet biotherapeutics is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bispecific, bifunctional action.
SONN Ratings Summary
SONN Quant Ranking